Agios Pharmaceuticals (AGIO) to Release Quarterly Earnings on Wednesday
Agios Pharmaceuticals (NASDAQ:AGIO) is set to issue its quarterly earnings data before the market opens on Wednesday, February 14th. Analysts expect the company to announce earnings of ($1.65) per share for the quarter.
Shares of Agios Pharmaceuticals (NASDAQ AGIO) opened at $76.93 on Tuesday. Agios Pharmaceuticals has a 52 week low of $45.11 and a 52 week high of $82.96. The company has a market cap of $3,750.00, a PE ratio of -12.27 and a beta of 2.12.
In other news, insider Carman Alenson sold 2,150 shares of the business’s stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $75.00, for a total transaction of $161,250.00. Following the completion of the transaction, the insider now directly owns 2,150 shares of the company’s stock, valued at $161,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 3,838 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $59.37, for a total transaction of $227,862.06. Following the transaction, the director now directly owns 80,851 shares of the company’s stock, valued at $4,800,123.87. The disclosure for this sale can be found here. In the last quarter, insiders sold 183,114 shares of company stock worth $13,866,025. Insiders own 5.43% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.watchlistnews.com/agios-pharmaceuticals-agio-to-release-quarterly-earnings-on-wednesday/1862175.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.